Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
NCT04342962 · Gruppo Italiano Malattie EMatologiche dell'Adulto · PHASE2 · terminated · last registry update 2025-01-30 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor enrollment” | Open Targets' class: insufficient enrollment | Registry record, Gruppo Italiano Malattie EMatologiche dell'Adulto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL3RA in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-06Results posted on the registry: Washington University School of Medicine, Flotetuzumab (NCT04582864)
- 2024-12-06Also stopped (terminated): Washington University School of Medicine, Flotetuzumab (NCT04582864)
- 2024-10-17Also stopped (terminated): Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-21Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-01Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp (NCT02113982)
- 2024-03-08Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Azacitidine + Tagraxofusp-erzs (NCT05720988)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision